<DOC>
	<DOCNO>NCT02825914</DOCNO>
	<brief_summary>Casein glycomacropeptide ( CGMP ) anti-inflammatory property experimental rodent colitis use human vitro inflammation model . Its use food ingredient proven safe influence dietary intake . In pilot study investigator find , orally administer CGMP seem beneficial effect comparable mesalazine active distal ulcerative colitis . The investigator wish evaluate effect large group patient active ulcerative colitis study clinical effect assess anti-inflammatory microbiome modulating property .</brief_summary>
	<brief_title>CAsein GLycomacropeptide Ulcerative Colitis - Anti-Inflammatory Microbiome Modulating Effects ( CAGLUCIM )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Caseins</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>ulcerative colitis ( verified mucosal histology endoscopy ) Clinically active ulcerative colitis ( SCCAI â‰¥ 3 ) Endoscopically inactive disease ( Endoscopic Mayo Score 0 ) Lactose milk protein intolerance Celiac disease Not able understand speak Danish . Pregnant nursing . Growth pathogenic bacteria stool culture 4 week randomization ( Salmonella , Campylobacter , Yersinia Clostridium Difficile . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>glycopeptides</keyword>
	<keyword>human microbiome</keyword>
	<keyword>caseinomacropeptide</keyword>
	<keyword>whey protein</keyword>
	<keyword>dietary protein</keyword>
</DOC>